Trends of generic substitution in community pharmacies
- Dong‐Churl Suh
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The purpose of this study is to measure the rate of generic drug substitution by pharmacists, and factors influencing generic substitution, such as the extent of drugs listed on the formulary as well as physicians' and patients' acceptance rate of generic substitutes. A total of 9,328 prescription orders were retrospectively reviewed from 94 pharmacies which were selected at random. The substitution rate by pharmacists, which is the rate using the number of prescriptions eligible for substitution as the denominator, has risen from 47% in 1979 to 96% in 1997; double the rate over the past 20 years. The net substitution rate, which uses all prescriptions as the denominator, was 30% in 1997; over 4 times greater than the rate in 1979. Physicians wrote most prescriptions (86%) using the brand name of the drug, which has been the trend for the past 20 years. Of the prescriptions ordered by brand name, 47% were substitutable according to the New Jersey formulary. Of these prescriptions, prescribers allowed generic substitution 77% of the time. Out of these prescriptions, 97% of patients agreed to use a generic substitute if the physician approved of substitution. Generic substitution rates have increased, probably due to greater acceptance of generics by physicians and pharmacists as well as encouragement from external sources such as third party payers. Health care professionals, third parties, and patients all have an important role to play in order to increase the use of generics, and therefore reduce drug expenditures.
- Rankin, K. (1996) Generics: A prognosis on the industry. Drug Store News For The Pharmacist 6: pp. 13-20
- Solano AP, Pesanello PF. The Impact of Managed Care on the Generic Drug Industry. U.S. Pharmacist November 1997(Supplement: Generic Drug Industry): 4-5.
- Rankin, K. (1995) Where generics fit into the picture. Drug Store News For The Pharmacist 5: pp. 17-9
- Smith, MC. (1991) Pharmaceutical Marketing: Strategy and Cases. Haworth Press Inc, New York
- Shah, HK. (1985) The Next Decade in Generic Pharmaceuticals. Business Quarterly 50: pp. 95-9
- Anonymous. Setting the Highest Standards. US Pharmacist 1998(Supplement: Generic Drug Industry): 9-10.
- Rados, B. (1985) Generic Drugs: Cutting Cost, Not Corners. FDA Consumer 19: pp. 8-9
- Beavers N. Generics' fate in '98: A year of sorting things out. Drug Topics November 1997(Supplement: Generics): 8s-13s.
- Mangione RA. Understanding Generic Drug Equivalence. US Pharmacist January 1999; Generic Drug Industry: 51-60.
- Annotated 45: pp. 14-6
- Burton, T, Goldberg, T, Devito, C. A history of anti-substitution laws and their replacement by drug product substitution laws. In: Goldberg, T, DeVito, C, Raskin, I eds. (1986) Generic drug laws: A decade of trial-A prescription for progress. National Center for Health Services Research and Technology Assessment, U.S. Department of Health and Human Services, Washington DC
- Schweitzer, SO. (1997) Pharmaceutical Economics and Policy. Oxford University Press, New York
- New Jersey Statutes. Annotated. 1977:24:6E-1 et seq.
- New Jersey Generic Formulary: List of Interchangeable Drug Products. New Jersey Department of Health and Senior Services, Trenton
- Culkin, TT, Mendell, S. (1989) Generic Substitution' in New Jersey, 1979-87. American Pharmacy NS29: pp. 25-30
- SAS/STAT User's Guide, Version 6. SAS Institute, Cary, NC
- Robinson, A. (1995) After Years of Steady Growth, Winds of Restraint Blowing on Prescription Drug Industry. Canadian Medical Association Journal 153: pp. 85-8
- Saniell, J. (1996) Projecting Future Drug Expenditure. Am J Health Syst Pharm 53: pp. 139-50
- Bloom, BS, Wierz, DJ, Pauly, MV. (1986) Cost and Price of Comparable Branded and Generic Pharmaceuticals. JAMA 256: pp. 2523-30
- Carroll, NV, Siridhara, C, Fincham, JE. (1987) Factors Affecting Market Acceptance of Generic Drug Products: An Examination of Inherent Risk, Price, and Maximum Allowable Cost Coverage. Akron Business and Economic Review 18: pp. 11-8
- Carroll, NV. (1995) Impact of Generic and Therapeutic Interchange Incentives on Community Pharmacy. American Pharmacy NS35: pp. 27-34
- Anis, AH. (1994) Substitution Laws, Insurance Coverage, and Generic Drug Use. Med Care 32: pp. 240-56
- Banahan, BF, Kolassa, EM. (1997) A Physician Survey on Generic Drugs and Substitution of Critical Dose Medications. Arch Intern Med 157: pp. 2080-8
- Shulkin, DJ, Giardino, AP, Freenock, TF, Henriksen, DS, Richman, C, Friedlander, MS (1992) Generic versus brand drug prescribing by resident physicians in Pennsylvania. Am Soc Hosp Pharm 49: pp. 625-6
- Southwick, K. (1997) Branded vs. Generics: Questions on bioequivalence mean state challenges to MCO substitution practices. Managed Healthcare 7: pp. 33-46
- Stone, J. (1986) Competitive Incentive Program Analysis And Proposal. American Pharmacy NS26: pp. 45-9
- Smith, DG. (1993) The Effects of Copayments and Generic Substitution on the Use and Cost of Prescription Drugs. Inquiry 30: pp. 189-98
- Rheinstein, PH. (1993) The Generic Drug Approval Process. Am Fam Physician 48: pp. 1357-60
- Epstien D. Generic Companies at Risk Despite Growing Acceptance. Drug Topics 1997; Generics(Supplement): 26s-7s.
- Maline, N. (1996) What pharmacists really think about brand substitutions. Drug Store News For The Pharmacist 6: pp. 23-30
- Huttin, C. (1999) Drug price divergence in Europe: Regulatory aspects. Health Affairs 18: pp. 245-9
- Kanavos, P, Mossialos, E. (1999) Outstanding regulatory aspects in the European pharmaceutical market. PharmacoEconomics 15: pp. 519-33
- Trends of generic substitution in community pharmacies
Pharmacy World and Science
Volume 21, Issue 6 , pp 260-265
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers
- Additional Links
- Brand name drugs
- Drug formulary
- Generic substitution
- Physician allowance
- Pharmacist substitution
- Pharmacy practice
- Industry Sectors